References
1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100. 2010/03/12. DOI: 10.1086/651263.
2. des Champs-Bro B, Leroy-Cotteau A, Mazingue F, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther 2011; 36: 152-160. 2011/03/04. DOI: 10.1111/j.1365-2710.2010.01166.x.
3. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012; 96: 748-757. 2012/11/01. DOI: 10.1007/s12185-012-1210-y.
4. Kobayashi R, Hori D, Sano H, et al. Risk Factors for Invasive Fungal Infection in Children and Adolescents With Hematologic and Malignant Diseases: A 10-year Analysis in a Single Institute in Japan.Pediatr Infect Dis J 2018; 37: 1282-1285. 2018/11/09. DOI: 10.1097/INF.0000000000002010.
5. Johnson LB and Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637. 2003/02/21. DOI: 10.1086/367933.
6. Hohmann N, Kocheise F, Carls A, et al. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. Clin Pharmacokinet 2016; 55: 1535-1545. 2016/05/30. DOI: 10.1007/s40262-016-0416-1.
7. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2012; 52: 195-203. 2011/03/09. DOI: 10.1177/0091270010395510.
8. Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 2012; 55: 483-492. 2012/03/21. DOI: 10.1111/j.1439-0507.2012.02186.x.
9. Hope WW. Population pharmacokinetics of voriconazole in adults.Antimicrob Agents Chemother 2012; 56: 526-531. 2011/11/09. DOI: 10.1128/AAC.00702-11.
10. Qi F, Zhu L, Li N, et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents 2017; 49: 403-409. 2017/02/06. DOI: 10.1016/j.ijantimicag.2016.11.025.
11. Xu G, Zhu L, Ge T, et al. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation. Int J Antimicrob Agents 2016; 47: 439-445. 2016/05/18. DOI: 10.1016/j.ijantimicag.2016.02.016.
12. Tang D, Song BL, Yan M, et al. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach. Basic Clin Pharmacol Toxicol2019; 125: 34-43. 2019/02/05. DOI: 10.1111/bcpt.13208.
13. T, Eguchi S and Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 2013; 28: 28-37. 2012/11/21. DOI: 10.2133/dmpk.dmpk-12-rv-085.
14. Kiang TK, Sherwin CM, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet 2012; 51: 515-525. 2012/06/09. DOI: 10.2165/11634080-000000000-00000.
15. Liu P and Mould DR. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother 2014; 58: 4727-4736. 2014/06/11. DOI: 10.1128/AAC.02809-13.
16. Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet2011; 50: 201-214. 2011/02/08. DOI: 10.2165/11538690-000000000-00000.
17. Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Antimicrob Agents Chemother 2010; 54: 4424-4431. 2010/08/04. DOI: 10.1128/AAC.00504-10.
18. Chen C, Yang T, Li X, et al. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation. Eur J Drug Metab Pharmacokinet 2019; 44: 659-668. 2019/05/02. DOI: 10.1007/s13318-019-00556-w.
19. Liu Y, Qiu T, Liu Y, et al. Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.Clin Ther 2019; 41: 1151-1163. 2019/05/14. DOI: 10.1016/j.clinthera.2019.04.027.
20. Chen K, Zhang X, Ke X, et al. Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit2018; 40: 663-674. 2018/09/08. DOI: 10.1097/FTD.0000000000000561.
21. Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther 2017; 102: 45-51. 2016/12/17. DOI: 10.1002/cpt.583.
22. Gastine S, Lehrnbecher T, Muller C, et al. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.Antimicrob Agents Chemother 2018; 62 2017/10/19. DOI: 10.1128/AAC.01194-17.
23. Friberg LE, Ravva P, Karlsson MO, et al. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012; 56: 3032-3042. 2012/03/21. DOI: 10.1128/AAC.05761-11.
24. Saini L, Seki JT, Kumar D, et al. Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy. Can J Infect Dis Med Microbiol 2014; 25: 271-276. 2014/11/06. DOI: 10.1155/2014/214813.
25. Kang S, Yee J, Kim JY, et al. Factors Associated With Voriconazole Concentration in Pediatric Patients. Ther Drug Monit 2020; 42: 866-871. 2020/09/02. DOI: 10.1097/FTD.0000000000000804.
26. Veringa A, Geling S, Span LF, et al. Bioavailability of voriconazole in hospitalised patients. Int J Antimicrob Agents 2017; 49: 243-246. 2016/12/26. DOI: 10.1016/j.ijantimicag.2016.10.010.
27. Kato K, Nagao M, Yamamoto M, et al. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. J Infect Chemother 2016; 22: 27-31. 2015/11/06. DOI: 10.1016/j.jiac.2015.09.008.
28. Hirata A, Noto K, Ota R, et al. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin. Int J Clin Pharmacol Ther 2019; 57: 135-143. 2019/01/29. DOI: 10.5414/CP203345.
29. Blanco Dorado S, Maronas Amigo O, Latorre-Pellicer A, et al. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. Br J Clin Pharmacol 2020; 86: 1661-1666. 2020/02/29. DOI: 10.1111/bcp.14267.
30. Cojutti P, Candoni A, Forghieri F, et al. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. Basic Clin Pharmacol Toxicol 2016; 118: 474-479. 2015/11/18. DOI: 10.1111/bcpt.12530.
31. Allegra S, De Francia S, De Nicolo A, et al. Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients.Eur J Drug Metab Pharmacokinet 2020; 45: 405-412. 2020/01/23. DOI: 10.1007/s13318-019-00603-6.
32. Allegra S, Fatiguso G, De Francia S, et al. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol 2018; 84: 197-203. 2017/08/15. DOI: 10.1111/bcp.13401.
33. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.Bone Marrow Transplant 2005; 35: 509-513. 2005/01/18. DOI: 10.1038/sj.bmt.1704828.
34. Vreugdenhil B, van der Velden W, Feuth T, et al. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol 2018; 84: 1980-1988. 2018/05/11. DOI: 10.1111/bcp.13627.
35. Ter Avest M, Veringa A, van den Heuvel ER, et al. The effect of inflammation on voriconazole trough concentrations in children. Br J Clin Pharmacol 2017; 83: 678-680. 2016/11/20. DOI: 10.1111/bcp.13151.
36. Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 2014; 15: 1065-1078. 2014/08/02. DOI: 10.2217/pgs.14.53.
37. Takahashi T, Mohamud MA, Smith AR, et al. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation. Antimicrob Agents Chemother2021; 65: e0062321. 2021/06/08. DOI: 10.1128/AAC.00623-21.
38. Wang J, Xu H, Li R, et al. Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children. Antimicrob Agents Chemother 2021; 65: e0049321. 2021/06/22. DOI: 10.1128/AAC.00493-21.
39. Farkas A, Daroczi G, Villasurda P, et al. Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.Antimicrob Agents Chemother 2016; 60: 6806-6812. 2016/09/08. DOI: 10.1128/AAC.00970-16.
40. Shi C, Xiao Y, Mao Y, et al. Voriconazole: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet 2019; 58: 687-703. 2019/01/29. DOI: 10.1007/s40262-019-00735-7.
41. Li ZW, Peng FH, Yan M, et al. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients. Ther Drug Monit 2017; 39: 422-428. 2017/06/13. DOI: 10.1097/FTD.0000000000000425.
42. Tang D, Yan M, Song BL, et al. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study. Br J Clin Pharmacol 2021; 87: 1890-1902. 2020/10/04. DOI: 10.1111/bcp.14578.
43. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.Antimicrob Agents Chemother 2002; 46: 2546-2553. 2002/07/18. DOI: 10.1128/AAC.46.8.2546-2553.2002.
44. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172. 2004/05/25. DOI: 10.1128/AAC.48.6.2166-2172.2004.
45. Wang T, Chen S, Sun J, et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother 2014; 69: 463-470. 2013/10/03. DOI: 10.1093/jac/dkt369.
46. Theuretzbacher U, Ihle F and Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-663. 2006/06/29. DOI: 10.2165/00003088-200645070-00002.
47. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Antimicrob Agents Chemother 2010; 54: 4116-4123. 2010/07/28. DOI: 10.1128/AAC.00896-10.
48. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol2009; 68: 906-915. 2009/12/17. DOI: 10.1111/j.1365-2125.2009.03534.x.
49. Muto C, Shoji S, Tomono Y, et al. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects. Antimicrob Agents Chemother 2015; 59: 3216-3223. 2015/03/25. DOI: 10.1128/AAC.04993-14.
50. Karlsson MO, Lutsar I and Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-944. 2008/12/17. DOI: 10.1128/AAC.00751-08.
51. Wei X, Zhao M, Fu P, et al. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study. J Chemother 2019; 31: 401-407. 2019/07/31. DOI: 10.1080/1120009X.2019.1646974.
52. Dote S, Sawai M, Nozaki A, et al. A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci 2016; 2: 10. 2016/04/21. DOI: 10.1186/s40780-016-0044-9.
53. Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol 2018; 84: 1587-1597. 2018/04/03. DOI: 10.1111/bcp.13595.
54. Chantharit P, Tantasawat M, Kasai H, et al. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization. Ther Drug Monit 2020; 42: 872-879. 2020/09/19. DOI: 10.1097/FTD.0000000000000799.
Table1.Demographic and clinical information